Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)
Medical Provider Experience and Assessment on Documenting Prescribing and Plan of Care Changes Due to Pharmacogenomics Testing
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Florida
-
Land O' Lakes, Florida, United States, 33558
- DCABM
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Must be a Medical Practitioner
- Medical Doctor (MD)
- Doctor of Osteopathic (DO)
- Physician Assistant (PA)
- Advanced Practice Registered Nurse (APRN)
- Nurse Practioner (NP)
- Must have a current standard operating procedure that includes obtaining/reviewing medical history.
Exclusion Criteria:
- Government-funded insurance data cannot be included in the study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Provider Structures and Processes
Time Frame: 36 months
|
Plan of Care Changes due to Pharmacogenomic testing.
Provider based observational survey system on the health and well-being of patients and populations
|
36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PAS1463
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacogenomic
-
NCT05036421CompletedPharmacokinetics | Pharmacogenomic
-
NCT05091879Active, not recruitingPolypharmacy | Pharmacogenomic Testing
-
NCT06334315RecruitingContraception | Pharmacogenomic Drug Interaction
-
NCT06660264Enrolling by invitationPharmacogenetics | Pharmacogenomic Drug Interaction
-
NCT02738047RecruitingPharmacogenomic Testing for Medication Management
-
NCT07373470Not yet recruitingPharmacogenetics | Community Pharmacy Services | Depression - Major Depressive Disorder | Pharmacogenomic Drug Interaction
-
NCT05037305Active, not recruitingPharmacogenomic Testing
-
NCT07216846RecruitingFall | Pharmacogenomic Testing | Adverse Drug Events | Poly Pharmacy | Fall Accident | Pharmacogenomic Drug Interaction
-
NCT06448091RecruitingPharmacogenomic Drug Interaction
-
NCT05959187CompletedDepressive Disorder | Pharmacogenomic Drug Interaction
Clinical Trials on pharmacogenomic
-
NCT03370718CompletedMetastatic Carcinoma in the Adrenal Cortex | Stage III Adrenal Cortex Carcinoma AJCC v8 | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex Carcinoma
-
NCT03216499CompletedRecurrent Glioblastoma
-
NCT02542397TerminatedMalignant Tumor of Ill-defined Site
-
NCT04984538WithdrawnElderly | Adverse Drug Event | Pharmacogenomics | Drug Drug Interaction
-
NCT05053815Enrolling by invitationPolypharmacy | Pharmacogenomics
-
NCT03803293Completed
-
NCT04893395WithdrawnDepressive Disorder, Major | Pharmacogenetics | Medication Therapy Management
-
NCT04500301CompletedDepression | Pain | Cancer
-
NCT04727827CompletedOncology | Hematopoietic Cell Transplantation
-
NCT00967200CompletedCentral Nervous System Lymphoma